---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058747"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:36:50.164479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M

## Summary
- Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.
- Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.
- GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.
- Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.
- Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025.

## SEC filing metadata
- accession: 0001104659-24-058747
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/0001104659-24-058747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/tm2413603d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058747
- JSON: https://secwatch.observer/filing/0001104659-24-058747.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058747.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported first quarter ended March 31, 2024 results: net income $36.5 million, or $0.58 basic per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $36.5 million, or $0.58 basic per share
  - Result: reported results
  source text: Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465924058747/0001104659-24-058747-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.